Market Research Report
Chronic Venous Ulceration (CVU) - Market Insights, Epidemiology and Market Forecast- 2030
|Chronic Venous Ulceration (CVU) - Market Insights, Epidemiology and Market Forecast- 2030|
DelveInsight Business Research LLP
Content info: 200 Pages
Delivery time: 2-10 business days
DelveInsight's 'Chronic Venous Ulceration (CVU) - Market Insights, Epidemiology and Market Forecast- 2030' report delivers an in-depth understanding of the CVU, historical and forecasted epidemiology as well as the CVU market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The CVU market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM CVU market size from 2017 to 2030. The report also covers current CVU treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2017-2030
Chronic Venous Ulceration (CVU) Overview
Chronic vein ulceration (CVU) is a defect in the skin below the level of the knee that occurs due to improper functioning of venous valves, persisting for more than six weeks with no tendency to heal after three or more months. Hence, also known as leg ulcers or lower limb ulcers or venous ulcers, or venous insufficiency or stasis ulcer.cancerous or cells along the lining of the colon or rectum mutate and grow out of control, forming a tumor.
The venous abnormality that leads to venous leg ulceration may involve abnormalities at different locations in the venous system, of different extent, and different etiologies. Possible causes of venous ulcers include inflammatory processes resulting in leukocyte activation, endothelial damage, platelet aggregation, and intracellular edema. Venous ulcers are often recurrent, and open ulcers can persist from weeks to many years. Severe complications include cellulitis, osteomyelitis, and malignant change. Although the overall prevalence is relatively low, the refractory nature of these ulcers increase the risk of morbidity and mortality and have a significant impact on patient quality of life
The pathophysiology of venous ulcers is not entirely clear. Venous incompetence and associated venous hypertension are thought to be the primary mechanisms for ulcer formation. Factors that may lead to venous incompetence include immobility; ineffective pumping of the calf muscle; and venous valve dysfunction from trauma, congenital absence, venous thrombosis, or phlebitis.
Risk factors for venous ulcers include varicose veins, history of blood clots in the legs (deep vein thrombosis), blockage of the lymph vessels, which causes fluid to build up in the legs, older age, being female, or being tall, family history of venous insufficiency, obesity, pregnancy, smoking, sitting or standing for long periods (usually for work) and fracture of a long bone in the leg or other serious injuries, such as burns or muscle damage. The symptoms of a venous ulcer include pain, itching, and swelling in the affected area. There may also be discolored, or hardened skin around the ulcer, and the sore may produce a foul-smelling discharge.
Chronic Venous Ulceration (CVU) Diagnosis
On physical examination, venous ulcers are generally irregular and shallow. Granulation tissue and fibrin are often present in the ulcer base. Other findings include lower extremity varicosities, edema, venous dermatitis associated with hyperpigmentation and hemosiderosis or hemoglobin deposition in the skin, and lipodermatosclerosis associated with thickening and fibrosis of normal adipose tissue under the skin.
Currently, widely available duplex scanning is considered the standard test of choice. Venography and imaging with contrast CT scan or MR venography are used infrequently and usually only when there is uncertainty about the Duplex scan information. Other methods of diagnosing venous diseases such as plethysmography and handheld Doppler do not give a good indication of the sites of venous incompetence. In a Duplex scan for chronic venous disease, the deep veins, superficial veins, and the communicating veins are evaluated.
Chronic Venous Ulceration (CVU) Treatment
Treatment options for venous ulcers include conservative management, mechanical treatment, medications, and surgical options. In general, treatment goals are to reduce edema, improve ulcer healing, and prevent a recurrence. Treatment must be multidisciplinary and individualized according to the characteristics of the patient and the illness.
Compression therapy is the standard of care for venous ulcers and chronic venous insufficiency. Studies have found that venous ulcers heal more quickly with compression therapy than without. This reduces edema in the leg that is considered to impede the healing process. The compression may be applied by either bandage or by compression stockings. In patients with an open ulcer, bandages are normally preferred because the exudate damages the stockings and shortens their lifespan. Presently, five categories of the extremities' compression therapy are available: compression bandages, compression stockings, self-adjustable Velcro devices, compression pumps, and hybrid devices. Compression bandages and compression stockings are most commonly used for short-term application after varicose vein interventions. Methods include inelastic, elastic, and intermittent pneumatic compression. Compression therapy reduces edema, improves venous reflux, enhances healing of ulcers, and reduces pain. Success rates range from 30-60% at 24 weeks and 70-85% after one year. After an ulcer has healed, lifelong maintenance of compression therapy may reduce the risk of recurrence.
Pentoxifylline (400 mg three times per day) has been shown to be an effective adjunctive treatment for venous ulcers when added to compression therapy. Pentoxifylline may also be useful as monotherapy in patients who are unable to tolerate compression bandaging. Like pentoxifylline therapy, aspirin (300 mg per day) combined with compression therapy has been shown to increase ulcer healing time and reduce ulcer size, compared with compression therapy alone. Bacterial colonization and superimposed bacterial infections are common in venous ulcers and contribute to poor wound healing. Oral antibiotics are recommended to treat venous ulcers only in cases of suspected cellulitis. Suspected osteomyelitis warrants an evaluation for arterial disease and consideration of intravenous antibiotics to treat the underlying infection. The role of surgery is to reduce venous reflux, hasten healing, and prevent ulcer recurrence. Surgical options for treatment of venous insufficiency include ablation of the saphenous vein; interruption of the perforating veins with subfascial endoscopic surgery; treatment of iliac vein obstruction with stenting; and removal of incompetent superficial veins with phlebectomy, stripping, sclerotherapy, or laser therapy.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Cases of Venous Ulcers, Diagnosed Prevalent Cases of Venous Ulcers , Diagnosed Prevalent Cases of Venous Leg Ulcers, Type-specific Distribution of Venous Ulcers, Gender-specific Distribution of Venous Ulcers and Age-specific Distribution of Venous Ulcers in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.
This section provides glimpse of the Venous Ulcers epidemiology in the 7MM.
The epidemiology segment also provides the Chronic Venous Ulceration (CVU)epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The drug chapter segment of the Chronic Venous Ulceration (CVU) report encloses the detailed analysis of Chronic Venous Ulceration (CVU) marketed drugs and mid and late stage pipeline drugs. It also helps to understand the Chronic Venous Ulceration (CVU) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.
Chronic Venous Ulceration (CVU) Emerging Drugs
Allogeneic ABCB5-positive Stem Cells: Rheacell
Allo-APZ2-CVU is being developed by Rheacell, a subsidiary of Ticeba, for the treatment of CVU. Administering ABCB5-positive stem cells to the patients leads to anti-inflammation by interacting with immune cells (e.g., macrophages, T-cells, B-cells), switching from a pro-inflammatory to an anti-inflammatory environment giving the body a chance to heal.These ABCB5+ MSCSs are classified by the European Medicines Agency (EMA) as an Advanced Therapy Medicinal Product (ATMP) manufactured by Ticeba in a patented process.
Product details in the report…
EscharEx is a topical biological drug candidate for the debridement of chronic and other hard-to-heal wounds using the same proteolytic enzyme technology as NexoBrid. It is a mixture of proteolytic enzymes for the management of the debridement of chronic and other hard-to-heal wounds. It is easy to use, and it is a non-surgical topical application that demonstrated safety and efficacy in the debriding of chronic wounds in several etiologies within a few daily applications..
Product details in the report…
TTAX01: Tissue Tech
TTAX01 is being developed by Tissue tech for the management of venous leg ulcers and non-healing wounds. It is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. It is based on the company's proprietary technology CRYOTEK process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue are being used. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP).
Product details in the report…
Complex wounds are those that do not heal after 3 months or more. These wounds are a significant burden on the healthcare system and result in patient and caregiver stress, economic loss, and decreased quality of life. Chronic wounds are those wounds that fail to heal promptly or become stuck in the inflammatory phase of healing. The most common types of chronic wounds are venous leg ulcers (VLUs), diabetic foot ulcers (DFUs), and pressure ulcers (PUs).
The current treatment modalities for venous ulcers include conservative management, mechanical modalities, medications, advanced wound therapy, and surgical options. Although the main goal of treatment is ulcer healing, secondary goals include reducing edema and preventing recurrence. Evidence-based treatment options for venous ulcers include leg elevation, compression therapy, dressings, pentoxifylline, and aspirin therapy. Topical antiseptics, including cadexomer iodine (Iodosorb), povidone-iodine (Betadine), peroxide-based preparations, honey-based preparations, and silver, have also been used to treat venous ulcers. Surgical management may be considered for ulcers that are large in size, of prolonged duration, or refractory to conservative measures. Compression therapy is a gold standard treatment modality for the initial and long-term treatment of venous ulcers in patients without the concomitant arterial disease. Dressings are recommended to cover ulcers and promote moist wound healing. Dressings are chosen based on wound location, size, depth, moisture balance, infection presence, allergies, comfort, odor management, ease and frequency of dressing changes, cost, and availability.
Antibiotics such as aspirin, pentoxifylline, phlebotonics, and other non-inflammatory medications are preferred to combat the ulcer. Venous ulcers that do not improve within four weeks of standard wound care should prompt consideration of adjunctive treatment options, which include skin grafting and the use of cellular and tissue-based products. Like conservative therapies, the goal of operative and endovascular management of venous ulcers (i.e., endovenous ablation, ligation, subfascial endoscopic perforator surgery, and sclerotherapy) is to improve healing and prevent ulcer recurrence.
In terms of current emerging therapies, the pipeline of CVUs holds potential products by several key players, such as Rheacell (Allogeneic ABCB5-positive Stem Cells), Tissue Tech (TTAX01 Allograft), and MediWound (EscharEx). Overall, the increasing prevalence of the disease and the promising emerging pipeline therapies will fuel the market during the forecasted period of 2017-2030.
This section includes a glimpse of the CVU 7MM market.
This section provides the total Chronic Venous Ulceration (CVU) market size and market size by therapies in the United States.
The total Chronic Venous Ulceration (CVU) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
The total Chronic Venous Ulceration (CVU) market size and market size by therapies in Japan are provided.
This section focusses on the rate of uptake of the potential drugs recently launched in the Chronic Venous Ulceration (CVU) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Chronic Venous Ulceration (CVU) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Chronic Venous Ulceration (CVU) Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Chronic Venous Ulceration (CVU) emerging therapies.
Competitive Intelligence Analysis
We perform competitive and market Intelligence analysis of the Chronic Venous Ulceration (CVU) market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Current Treatment Scenario, Marketed Drugs and Emerging Therapies: